Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Ohio

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Legal Recourse

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and legal recourse. Within this broad context, the dissemination of knowledge about pharmaceutical therapies and their potential adverse effects has been a critical function. As the domain of mass production expands, the focus necessarily shifts from population-level health education to the specific, tangible consequences faced by individuals in occupational and therapeutic settings. This transition is particularly salient when considering the intersection of biologic drug manufacturing and patient safety. The historical emphasis on general health literacy provides the necessary framework for now examining a more targeted concern: the exposure to Tysabri (natalizumab) and the associated risk of progressive multifocal leukoencephalopathy (PML). In the context of mass production, this concern moves from abstract awareness to a concrete occupational and patient-centered issue. For individuals in Ohio who have been prescribed or exposed to Tysabri, understanding the legal parameters—specifically the statute of limitations for filing a settlement claim related to PML—becomes paramount. This pivot from general health information to a specific legal and medical exposure scenario underscores the need for precise, actionable knowledge within the mass production framework, where the legacy of broad education now serves a more focused, risk-aware purpose.

Understanding Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal timelines is critical when considering settlement options. The prescribing information for Tysabri contains a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy, and physicians must weigh expected benefits against PML risk.

Clinical Presentation and Diagnosis of PML

PML typically presents with progressive neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed through brain MRI and detection of JC virus DNA in cerebrospinal fluid. The clinical course is often devastating, with most patients experiencing severe disability or death. The label explicitly states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled replication in oligodendrocytes. This leads to demyelination and progressive neurological injury. The risk is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have prior immunosuppressant exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Patient Monitoring

Regarding the adequacy of warnings, the Tysabri label includes a boxed warning and detailed precautions. Patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified. Despite these measures, questions may arise about whether prescribers adequately communicated the PML risk to patients, particularly regarding the significance of anti-JCV antibody testing and the cumulative risk over time.

Statute of Limitations for Tysabri Claims in Ohio

For Ohio patients considering settlement, the statute of limitations is a key factor. In Ohio, personal injury claims generally must be filed within two years from the date the injury is discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. PML may develop months to years after starting Tysabri, and symptoms can be subtle initially. The label notes that herpes infections have occurred "a few months to several years" after starting Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and similar latency applies to PML. The discovery date for statute of limitations purposes is typically when the patient receives a confirmed PML diagnosis or when symptoms become clearly attributable to the drug.

Settlement Considerations for Affected Patients

Settlement considerations for affected patients include the severity of neurological impairment, medical expenses, lost income, and pain and suffering. Because PML often leads to permanent disability, settlements may need to account for long-term care needs. Patients should document the timing of Tysabri treatment, onset of symptoms, diagnostic confirmation, and any communications with healthcare providers about PML risk. Legal counsel experienced in pharmaceutical litigation can help assess whether the statute of limitations has been met and what evidence is needed to support a claim.

Summary and Next Steps

In summary, Tysabri carries a known risk of PML, with specific risk factors and a requirement for patient monitoring. Ohio patients who develop PML should be aware of the two-year statute of limitations from discovery of injury and should seek prompt legal evaluation. The medical evidence underscores the importance of early diagnosis and treatment discontinuation, but the prognosis remains poor for many patients.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

In Ohio, personal injury claims generally must be filed within two years from the date the injury is discovered or reasonably should have been discovered. For PML, the discovery date is typically when the patient receives a confirmed PML diagnosis or when symptoms become clearly attributable to Tysabri. It is crucial to consult with an attorney promptly to ensure the claim is filed within the applicable deadline.

What are the risk factors for developing PML from Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy.

How is PML diagnosed?

PML is diagnosed through brain MRI and detection of JC virus DNA in cerebrospinal fluid. Symptoms include progressive neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. The label states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.